February 2026

New Products

• Delgocitinib (Anzupgo) is a pan Janus kinase (JAK) inhibitor that targets the activity of all four members of the JAK family of enzymes consisting of JAK1, JAK2, JAK3, and tyrosine kinase 2 in a concentration dependent manner. In human cellular studies, inhibition of the JAK-STAT pathway by delgocitinib attenuates the signalling of several pro-inflammatory cytokines (including interleukin (IL)-2, IL-4, IL-6, IL-13, IL-21, IL-23, granulocyte-macrophage-colony-stimulating factor, and interferon-α), downregulating the immune and inflammatory responses in cells of relevance to chronic hand eczema (CHE) pathology. Anzupgo is indicated for the treatment of moderate to severe CHE in adults for whom topical corticosteroids are inadequate or inappropriate. Anzupgo cream contains delgocitinib 2% and is available in 15 g or 60 g tubes.
   
• Landiolol hydrochloride (Rapiblyk) is a highly selective beta-1-adrenoreceptor antagonist (the selectivity for beta-1 receptor blockade is 255 times higher than for beta-2-receptor blockade) that inhibits the positive chronotropic effects of the catecholamines adrenaline and noradrenaline on the heart, where beta-1-receptors are predominantly located. Landiolol, as other beta-blockers, is thought to reduce the sympathetic drive, resulting in reduction in heart rate, decrease in spontaneous firing of ectopic pacemakers, slowing the conduction and increasing the refractory period of the atrioventricular (AV) node. In clinical studies, landiolol controlled tachycardia in an ultra-short acting manner with a fast onset and offset of action and further demonstrated anti-ischaemic and cardioprotective effects. Rapiblyk is indicated in adults for supraventricular tachycardia and for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other circumstances where short-term control of the ventricular rate with a short acting agent is desirable; and for non-compensatory sinus tachycardia where, in the physician’s judgment the rapid heart rate requires specific intervention. It is not intended for use in chronic settings. Rapiblyk is contraindicated in severe bradycardia (less than 50 beats per minute); sick sinus syndrome without pacemaker; severe AV nodal conductance disorders (without pacemaker): 2nd or 3rd degree AV block; cardiogenic shock; severe hypotension; decompensated heart failure when considered not related to the arrhythmia; pulmonary hypertension; non-treated phaeochromocytoma; acute asthmatic attack; and severe, uncorrectable metabolic acidosis. Rapiblyk powder for infusion contains landiolol hydrochloride 300 mg and is available in packs of 1 vial.
   
• Lutetium (¹⁷⁷Lu) oxodotreotide (Lutathera) has a high affinity for subtype 2 somatostatin receptors (SST₂). It binds to malignant cells which express SST₂. Lutetium-177 is a beta-minus emitting radionuclide with a maximum penetration range in tissue of 2.2 mm (mean penetration range of 0.67 mm), causing death of the targeted tumour cells with a limited effect on neighbouring normal cells. Lutathera is indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, including foregut, midgut, and hindgut neuroendocrine tumours in adults. Lutathera is contraindicated in patients with kidney failure with creatinine clearance < 30 mL/min; in patients with hypersensitivity to one or more amino acids or congenital abnormality of amino acid metabolism; and in established or suspected pregnancy or when pregnancy has not been excluded. Lutathera solution for infusion contains lutetium (¹⁷⁷Lu) oxodotreotide 370 mBq per 1 mL and is available in packs of 1 vial.
  
  Pyrazinamide (Pyrazinamide-AFT) is a prodrug that is converted to the active form pyrazinoic acid (POA) by pyrazinamidase/nicotinamidase encoded by the pncA gene in M. tuberculosis. Pyrazinamide is generally active only at an acid pH. The precise mechanism of action is unknown. Possible mechanisms of antibacterial activity include: (1) activation of the sigma factor (SigE)-dependent cell envelope stress response, (2) binding of POA to aspartate decarboxylase (PanD), and (3) POA binding to ribosomal protein S1 (RpsA) of M. tuberculosis. Inhibition of fatty acid synthesis may also contribute to the activity of POA. Pyrazinamide-AFT is indicated in adult patients of more than 12 years of age with active drug-sensitive tuberculosis caused by Mycobacterium tuberculosis. Pyrazinamide-AFT is an anti-tuberculosis agent used in combination with other anti-tuberculosis agents and is commonly used in the first 2 months of treatment. Pyrazinamide-AFT is contraindicated in patients with hepatic disease, hyperuricaemia and/or gouty arthritis. Pyrazinamide-AFT tablets contain pyrazinamide 500 mg and are available in packs of 100.
   
• Vanzacaftor (calcium), tezacaftor and deutivacaftor (Alyftrek) is a fixed combination of 2 cystic fibrosis transmembrane conductance regulator (CFTR) correctors and a potentiator. Vanzacaftor and tezacaftor bind to different sites on the CFTR protein and have an additive effect in facilitating the cellular processing and trafficking of select mutant forms of CFTR (including F508del-CFTR) to increase the amount of CFTR protein delivered to the cell surface compared to either molecule alone. Deutivacaftor potentiates the channel open probability (or gating) of the CFTR protein at the cell surface. The combined effect is increased quantity and function of CFTR at the cell surface, resulting in increased CFTR activity as measured both by CFTR mediated chloride transport in vitro and by sweat chloride in people with cystic fibrosis (CF). Alyftrek is indicated for the treatment of those who meet the diagnostic criteria for CF in people aged 6 years and older who have at least one mutation in the CFTR gene that is responsive based on clinical or in vitro evidence. Alyftrek tablets contain vanzacaftor 4 mg, tezacaftor 20 mg and deutivacaftor 50 mg available in packs of 84 or vanzacaftor 10 mg, tezacaftor 50 mg and deutivacaftor 125 mg available in packs of 56.

New Presentation

• Adrenaline (epinephrine) (neffy) is now available as a nasal spray. neffy is indicated for emergency treatment of type I allergic reactions, including anaphylaxis, in adults and children aged 4 years and older and weighing 15 kg or greater. neffy nasal spray contains adrenaline (epinephrine) 1 mg per 1 actuation or 2 mg per 1 actuation and is available in packs of 2 single use devices.
   
• Amikacin (sulfate) (Amikacin Kabi) is now available as a solution for infusion containing amikacin 500 mg per 100 mL and is available in packs of 10 bottles.
   
• Tenecteplase (rch) (Metalyse 25 mg) is now available in 25 mg powder for injection. Metalyse 25 mg is indicated in adults for the thrombolytic treatment of acute ischaemic stroke (AIS) within 4.5 hours from last known well and after exclusion of intracranial haemorrhage. Metalyse 25 mg is contraindicated in AIS without disabling neurological deficit; in situations associated with a risk of bleeding such as: history or evidence or suspicion of intracranial haemorrhage including subarachnoid haemorrhage, significant bleeding disorder at present or within the past 6 months, known haemorrhagic diathesis, active systemic non-compressible bleeding, patients with effective anticoagulation (e.g. INR > 1.7), any history of central nervous system damage (i.e. neoplasm, aneurysm, intracranial or spinal surgery), thoracic aortic dissection, severe uncontrolled arterial hypertension, prolonged or traumatic cardiopulmonary resuscitation (> 2 minutes) within the past 2 weeks, severe hepatic dysfunction (including hepatic failure, cirrhosis, portal hypertension (oesophageal varices) and active hepatitis), active peptic ulceration, arterial aneurysm and known arterial/venous malformation, neoplasm with increased bleeding risk, acute pericarditis and/or subacute bacterial endocarditis, acute pancreatitis; and in patients with known hypersensitivity to gentamicin. Metalyse 25 mg powder for injection contains tenecteplase 25 mg and is available in packs of 1 vial.

New Indications

• Binimetinib (Mektovi) and Encorafenib (Braftovi) in combination, are now also indicated for the treatment of adult patients with metastatic non-small cell lung cancer with a BRAF V600E mutation.
   
• Brentuximab vedotin (Adcetris) is now also indicated for the treatment of adult patients with previously untreated CD30+ Stage IIB with large mediastinal mass and/or extranodal disease, Stage III or Stage IV Hodgkin lymphoma in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone.
   
• Burosumab (Crysvita) is now also indicated for the treatment of fibroblast growth factor 23‑related hypophosphataemia in tumour induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in adults, adolescents and children 1 year of age or older.
   
• Mepolizumab (Nucala) is now also indicated as an add-on maintenance treatment for adult patients with uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils on stable inhaler triple therapy (or, where clinically required, an equivalent regimen).

New Contraindications

• Cinnarizine and dimenhydrinate (Cizinate) is now also contraindicated in children under 6 years of age because of the potential for fatal respiratory depression, psychiatric and central nervous system events.
   
• Ibuprofen and codeine phosphate hemihydrate (Nurofen Plus) is now contraindicated in all trimesters of pregnancy.
   
• Mitomycin (Mitomycin Omegapharm) is now also contraindicated in patients with pancytopenia or isolated leukopenia/thrombopenia, haemorrhagic diathesis, acute infections and breastfeeding. During systemic therapy, restrictive or obstructive disturbances to pulmonary ventilation, renal function, liver function and/or a poor general state of health are relative contraindications, and temporal connection with radiotherapy or other cytostatic may be a further contraindication. During intravesical therapy, perforation of the bladder wall is an absolute contraindication, and cystitis is a relative contraindication.
   
• Paracetamol and pseudoephedrine hydrochloride (Chemists’ Own Cold & Flu Relief) is now also contraindicated in patients with uncontrolled hypertension and severe acute or chronic kidney disease/renal failure.

This list is a summary of only some of the changes that have occurred over the last month.
Before prescribing, always refer to the full product information.